authors
- Paes, Bosco
- Tarride, Jean-Eric
- Joan L., Robinson
- Krista L., Lanctôt
- Bosco, Paes
- Charles, Hui
- Aaron, Chiu
- Jean-Eric, Tarride
Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- July 1, 2009
has subject area
- 11 Medical and Health Sciences (FoR)
- 14 Economics (FoR)
- Antibodies, Monoclonal (MeSH)
- Antibodies, Monoclonal, Humanized (MeSH)
- Canada (MeSH)
- Cohort Studies (MeSH)
- Cost-Benefit Analysis (MeSH)
- General & Internal Medicine (Science Metrix)
- Gestational Age (MeSH)
- Humans (MeSH)
- Infant, Newborn (MeSH)
- Infant, Premature (MeSH)
- Palivizumab (MeSH)
- Respiratory Syncytial Virus Infections (MeSH)
- Respiratory Syncytial Virus Vaccines (MeSH)